Wockhardt has received final USFDA approval for its generic prostrate cancer tablet abiraterone acetate. The drug in strength of 250mg is a generic version of Zytiga, marketed in US and other countries by Johnson & Johnson. Abiraterone is used to treat men with prostate cancer that has spread to other parts of the body.
The company will launch the product in the US in a short period of time and is being manufactured at a contract manufacturing facility, based near Hyderabad.
Company Profile : Wockhardt Ltd
Leave a Reply